A clinical trial performed by Queen Mary University of London has found that taking the drug Anastrozole decreases the risk of breast cancer by 53% in high-risk, postmenopausal women. Around 4,000 women from 18 countries were involved in the study and these women took the drug for five years. So, what does “high-risk” mean?
Women were considered high-risk if they had certain types of benign breast disease, two or more blood relatives with the disease, a sister/mother who developed breast cancer before age 50, or had a sister/mother with breast cancer in both breasts.
Anastrozole works by stopping the body from making estrogen, a hormone that fuels the growth of many breast cancers. This study revealed that anastrozole is more effective than tamoxifen, one of two drugs FDA-approved for breast cancer prevention, and has fewer side effects. Researchers working on the study recommend that anastrozole be added to the recommended drugs for women who are predisposed to developing breast cancer.
To read the complete study, click here.